BeiGene: Clinical Trials

74 trials sponsored by BeiGene, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

51 completed, 8 terminated, 5 recruiting, 4 unknown. 74 Phase 1, 20 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 174Completed 51, Terminated 8, Recruiting 5, Unknown 4, Active not recruiting 3, Withdrawn 2, Not yet recruiting 1
Phase 220Completed 10, Terminated 3, Active not recruiting 2, Recruiting 2, Unknown 2, Not yet recruiting 1

Follow BeiGene: new trials by email

Trials (filtered) newest first · largest first

All 74 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Sonrotoclax Plus Azacitidine in Patients With MDS-IB2
Sonrotoclax, Azacitidine (AZA) - Myelodysplastic Syndromes, High Risk
Phase 1 / Phase 2RecruitingShanghai General Hospital, Shanghai Jiao Tong University School of Medicine602026-10-152026-10-21
A Phase Ib Trial Evaluating the Safety and Activity of Neoadjuvant Combination of Tislelizumab Plus FLOT for Resectable Esophagogastric Adenocarcinoma
Tislelizumab, FLOT Chemotherapy - Esophagogastric Junction Adenocarcinoma, Gastric Adenocarcinoma
Phase 1RecruitingInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest182025-12-122025-12-19
Zanubrutinib in Combination With Pola-R-CHP and High-dose Methotrexate in Patients With Secondary CNS Lymphoma
Zanubrutinib, Methotrexate, Polatuzumab Vedotin - CNS Lymphoma
Phase 1RecruitingJuan P. Alderuccio, MD202025-04-172026-05-14
Effect of Phenytoin or Itraconazole on How BGB-16673 is Absorbed and Removed From the Body in Healthy Participants
BGB-16673, Itraconazole, Phenytoin - Healthy Volunteers
Phase 1CompletedBeiGene372025-04-032026-08-24
A Study of How [14C]-BGB-16673 is Absorbed, Broken Down, and Removed From the Body After a Single Oral Dose in Healthy Participants
[14C]-BGB-16673 - Healthy Volunteers
Phase 1CompletedBeiGene82025-01-242025-05-01
A Study of Different Forms of BGB-43395 and Food Effect in Healthy Participants
BGB-43395 - Healthy Volunteers
Phase 1CompletedBeiGene512025-01-142025-09-04
A Study of BGB-B3227 Alone and in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid Tumors
BGB-B3227, Tislelizumab, Chemotherapy - Advanced Cancer, Advanced Solid Tumor
Phase 1TerminatedBeiGene352024-09-112026-03-16
A Study to Evaluate the Effects of Phenytoin and Itraconazole on Sonrotoclax (BGB-11417) in Healthy Volunteers
Phenytoin, Itraconazole, sonrotoclax - Not Determined
Phase 1CompletedBeiGene302024-08-192024-11-27
Trametinib Plus Anlotinib Combined With Tislelizumab in KRAS-mutant NSCLC
Trametinib, Anlotinib, Tislelizumab - KRAS Mutation-Related Tumors, Advanced Lung Cancer
Phase 1 / Phase 2Not yet recruitingShanghai Chest Hospital602024-07-012024-06-13
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single- and Multiple-Ascending Doses and Food Effect of BGB-45035 in Healthy Participants and in Adults With Autoimmune Dermatological Diseases
BGB-45035, Placebo - Healthy Participants, Healthy Subjects
Phase 1CompletedBeiGene2032024-06-202026-06-22
A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
BG-68501, Fulvestrant, BGB-43395 - Breast Cancer, Small Cell Lung Cancer
Phase 1Active not recruitingBeiGene1032024-03-112026-10-20
Safety, Pharmacokinetics and Antitumor Activity of BGB-B167 Alone and in Combination With Tislelizumab in Participants With Solid Tumors in Chinese Participants
BGB-B167, Tislelizumab - Solid Tumors
Phase 1WithdrawnBeiGene2024-03-012023-11-29
Study to Evaluate the Bioavailability of Tislelizumab Via Subcutaneous Injection in First-Line Treatment of Participants With Advanced or Metastatic Non-Small Cell Lung Cancer
Tislelizumab IV, Tislelizumab SC, Histology-Based Chemotherapy Doublet - Non-small Cell Lung Cancer
Phase 1CompletedBeiGene622023-11-162026-08-12
A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies
PRT2527, Zanubrutinib, Venetoclax - Aggressive B-Cell Non-Hodgkin's Lymphoma (NHL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Phase 1CompletedPrelude Therapeutics Incorporated862023-09-122026-01-26
BGB-A3055 Alone and in Combination With Tislelizumab in Participants With Solid Tumors
BGB-A3055, Tislelizumab, Chemotherapy - Advanced Solid Tumor, Metastatic Solid Tumor
Phase 1TerminatedBeiGene992023-08-212026-03-13
A Study of BGB-30813 Alone or in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid Tumors
BGB-30813, Tislelizumab - Advanced Solid Tumors
Phase 1TerminatedBeiGene442023-07-192025-09-16
A Study to Investigate the Absorption, Metabolism and Excretion of [14C]-BGB-11417
[14C]-BGB-11417 - Healthy Volunteers
Phase 1CompletedBeiGene62023-05-222025-04-17
Bioequivalence of a Zanubrutinib Tablet Compared to Capsules in Healthy Adult Participants
Zanubrutinib - Healthy Volunteers
Phase 1CompletedBeiGene582023-03-072024-10-26
Study of IMX-110 in Combination With Tislelizumab in Patients With Advanced Solid Tumors
IMX-110 combined with Tislelizumab - Advanced Solid Tumor
Phase 1 / Phase 2UnknownImmix Biopharma, Inc.602023-02-032023-08-08
A Study Investigating the Efficacy and Safety of Alcestobart (LBL-007) Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer
Alcestobart, Tislelizumab, Bevacizumab or Bevacizumab biosimilar - Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer
Phase 1 / Phase 2Active not recruitingBeiGene1132023-01-292026-07-23

Showing 20 of 74. Sign in to see all of them.

Conditions studied

Stomach Neoplasms (5)  ·  Carcinoma, Non-Small-Cell Lung (4)  ·  Lymphoma, Large B-Cell, Diffuse (4)  ·  Neoplasm Metastasis (4)  ·  Triple Negative Breast Neoplasms (4)  ·  Breast Neoplasms (3)  ·  Carcinoma, Hepatocellular (3)  ·  Colorectal Neoplasms (3)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (3)  ·  Lymphoma (3)  ·  Lymphoma, B-Cell, Marginal Zone (3)  ·  Lymphoma, Mantle-Cell (3)  ·  Neoplasms (3)  ·  Small Cell Lung Carcinoma (3)  ·  Endometrial Neoplasms (2)

Interventions

tislelizumab (29)  ·  zanubrutinib (19)  ·  pamiparib (6)  ·  Carboplatin (4)  ·  Itraconazole (4)  ·  BGB-283 (3)  ·  Capecitabine (3)  ·  Docetaxel (3)  ·  Oxaliplatin (3)  ·  Paclitaxel (3)  ·  Pemetrexed (3)  ·  sitravatinib (3)  ·  130-nm albumin-bound paclitaxel (2)  ·  Cisplatin (2)  ·  Drug Therapy (2)

Countries

United States (38)  ·  China (32)  ·  Australia (31)  ·  South Korea (12)  ·  New Zealand (11)  ·  Spain (6)  ·  Taiwan (5)  ·  United Kingdom (5)  ·  France (4)  ·  Italy (4)  ·  Germany (3)  ·  Moldova (3)  ·  Georgia (2)  ·  Japan (2)  ·  Poland (2)

Top investigators

William Novotny, MD (4)  ·  William Novotony, MD (2)  ·  Baohui Han, MD, PhD (1)  ·  David Schiff, MD (1)  ·  Florian Lordick, Prof. Dr. (1)  ·  Jayesh Desai, MD (1)  ·  Juan P Alderuccio, MD (1)  ·  Lei Zhao (1)  ·  Lu Zhang, M.D. (1)  ·  Michael Millward, MD (1)  ·  Ranjit Bindra, MD (1)  ·  Salah Eddin Al-Batran, Prof. Dr. (1)

Results publications

PMID 32182156, PMID 35900694, PMID 36879284, PMID 38502198, PMID 38775302, PMID 29439186, PMID 31378459, PMID 32031037, PMID 32144955, PMID 32540858, PMID 33022066, PMID 33128299, PMID 33772633, PMID 33876576, PMID 34152395, PMID 34473343, PMID 34795408, PMID 35383885, PMID 35390135, PMID 36480811, PMID 36797356, PMID 37145975, PMID 37474720, PMID 37857528, PMID 38197138, PMID 38970256, PMID 39563886, PMID 41202501, PMID 41324998, PMID 41824782, PMID 42337921, PMID 42667590

NIH funding

2023 (3), 2017 (2), 2018 (2), 2016 (1), 2019 (1), UM1CA137443 (1)